Croucher, P., De Hendrik, R., Perry, M., Hijzen, A., Shipman, C., Lippitt, J., . . . Vanderkerken, K. (2003). Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Chicago-čujuhus (17. p.)Croucher, P., et al. Zoledronic Acid Treatment of 5T2MM-bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival. 2003.
MLA-čujuhus (9. p.)Croucher, P., et al. Zoledronic Acid Treatment of 5T2MM-bearing Mice Inhibits the Development of Myeloma Bone Disease: Evidence for Decreased Osteolysis, Tumor Burden and Angiogenesis, and Increased Survival. 2003.